Liberia vs Peru: Tuberculosis patients living with HIV receiving antiretroviral therapy
Liberia
705 patients
in 2021
Peru
732 patients
in 2021
Liberia rank
40th
Peru rank
39th
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Liberia
- Peru
How they compare
Peru currently reports 732 patients against 705 patients in Liberia, a difference of 27 patients.
Across all 14 years both countries report, Peru has been ahead every year.
Liberia ranks 40th and Peru ranks 39th of 183 countries.
Peru has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Liberia | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 30 patients | 125.5 patients | 95.5 patients | Peru |
| 2010s | 283.7 patients | 817.4 patients | 533.7 patients | Peru |
| 2020s | 695 patients | 730 patients | 35 patients | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Liberia or Peru?
- Peru, at 732 patients against 705 patients in Liberia as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Liberia and Peru?
- 27 patients, with Peru ahead.
- How many years of comparable data are there for Liberia and Peru?
- 14 years are reported by both, from 2008 to 2021.
- How do Liberia and Peru rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Liberia ranks 40th and Peru ranks 39th of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.